Commentary: Screening for prostate cancer
dc.contributor.author | Heyns C.F. | |
dc.date.accessioned | 2011-05-15T16:16:40Z | |
dc.date.available | 2011-05-15T16:16:40Z | |
dc.date.issued | 2007 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Note | |
dc.identifier.citation | International Journal of Epidemiology | |
dc.identifier.citation | 36 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 03005771 | |
dc.identifier.other | 10.1093/ije/dyl305 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/13882 | |
dc.subject | prostate specific antigen | |
dc.subject | age distribution | |
dc.subject | Canada | |
dc.subject | cancer mortality | |
dc.subject | cancer screening | |
dc.subject | cancer survival | |
dc.subject | clinical trial | |
dc.subject | Cochrane Library | |
dc.subject | cost effectiveness analysis | |
dc.subject | diagnostic value | |
dc.subject | early cancer | |
dc.subject | early diagnosis | |
dc.subject | evidence based medicine | |
dc.subject | human | |
dc.subject | male | |
dc.subject | note | |
dc.subject | priority journal | |
dc.subject | prostate biopsy | |
dc.subject | prostate cancer | |
dc.subject | quality of life | |
dc.subject | risk assessment | |
dc.subject | risk benefit analysis | |
dc.subject | risk reduction | |
dc.subject | survival time | |
dc.subject | systematic review | |
dc.title | Commentary: Screening for prostate cancer | |
dc.type | Note |